Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News PAVmed Inc PAVMZ


Primary Symbol: PAVM

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:PAVM)

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

PR Newswire 3 days ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

PR Newswire 4 days ago

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

PR Newswire 4 days ago

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

PR Newswire 6 days ago

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

PR Newswire 7 days ago

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire April 8, 2024

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

PR Newswire March 26, 2024

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PR Newswire March 21, 2024

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PR Newswire March 21, 2024

Opinion & Analysis (NDAQ:PAVM)

No current opinion is available.

Bullboard Posts (NDAQ:PAVM)

PAVmed Subsidiary, Veris Health, Signs Memorandum of Underst

JUST IN: $PAVM PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer...
whytestocks - 6 days ago

666

Sixes people!!!
greblokgreblok - June 7, 2021

One Year Later...

One year later and WE ARE COOKING WITH GAS!
greblokgreblok - February 11, 2021

still holding this stock

setting new highs this morning,so glta shareholders.
coolfooldumbguy - February 18, 2020

it's a buy today for me

this morning at $1.95 per share,so glta shareholders.
coolfooldumbguy - February 14, 2020

watching this one for

an entry position,it's doing a device for GERD,which is a common thing,and if this product is successful,this stock will be big,so...
coolfooldumbguy - February 11, 2020